Defence Therapeutics Inc.
DTCFF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.56M
Close$
$-0.00
101.5% downside
Current Fair Value
101.5% downsideOvervalued by 101.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $29.56 Million |
|---|---|
| Enterprise Value | $28.17 Million |
| Earnings per Share | $-0.05 |
| Beta | 1.35 |
| Outstanding Shares | 59,032,644 |
Return
| Return on Equity | -117.17% |
|---|---|
| Return on Assets | -67.17% |
| Return on Invested Capital | -71.47% |
Valuation & Multiples
| P/E Ratio | -3.49 |
|---|---|
| PEG | -1.65 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.65 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Defence Therapeutics Inc.
5 employees
CEO: Amie Phinney
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerst...